TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 24, 2006--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the fourth quarter and full year of 2005. Regeneron reported a net loss of $29.7 million, or $0.53 per share (basic and diluted), for the fourth quarter of 2005 and a net loss of $95.4 million, or $1.71 per share (basic and diluted), for the full year. Excluding the effects of expensing stock options in 2005, Regeneron had a net loss of $25.9 million, or $0.46 per share (basic and diluted), in the fourth quarter and a net loss of $75.5 million, or $1.35 per share (basic and diluted), for the full year 2005. In 2004, Regeneron reported net income of $2.8 million, or $0.05 per share (basic and diluted), for the fourth quarter and net income of $41.7 million, or $0.75 per basic share and $0.74 per diluted share, for the full year.
